CLINICAL TRIALS PROFILE FOR CILOXAN

All Clinical Trials for CILOXAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00855608 ↗	Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study	Unknown status	American University of Beirut Medical Center	Phase 1	2009-03-01	Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders. The eye is a self contained organ relatively isolated from the systemic circulation by the tight blood retinal barrier. Effective intraocular drug levels can be achieved with a much smaller amount of medication if injected intravitreally and this also results in minimal systemic exposure to the patient. Preliminary studies have shown that adalimumab may have a positive role in the management of uveitis in humans and can be an effective treatment intravitreally in animal models. No data has been published yet on intravitreal use of adalimumab in human subjects.
NCT00855608 ↗	Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study	Unknown status	Rafic Hariri University Hospital	Phase 1	2009-03-01	Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders. The eye is a self contained organ relatively isolated from the systemic circulation by the tight blood retinal barrier. Effective intraocular drug levels can be achieved with a much smaller amount of medication if injected intravitreally and this also results in minimal systemic exposure to the patient. Preliminary studies have shown that adalimumab may have a positive role in the management of uveitis in humans and can be an effective treatment intravitreally in animal models. No data has been published yet on intravitreal use of adalimumab in human subjects.
NCT00872209 ↗	Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa	Completed	Otic Pharma	Phase 1/Phase 2	2009-05-01	The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro, a novel medication developed to treat Acute Diffuse Otitis Externa of bacterial origin. The working hypothesis is that Foam Otic Cipro is as effective as registered ear drops.
NCT01157819 ↗	Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis	Completed	Otic Pharma	Phase 2	2010-07-01	The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro (0.3% Ciprofloxacin Otic Foam), used once-daily for 7 days for the treatment of Acute Diffuse Otitis Externa, compared to commercial ear drops used twice daily for 7 days.
NCT02223338 ↗	Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics	Completed	Loma Linda University	N/A	2014-10-01	1. Background: Over 1 million intravitreal injections are performed annually in the United States. The most devastating complication related to these injections is endophthalmitis, with an incidence of 0.02 - 0.1% per injection. Techniques aimed at prevention of this complication have been studied, though emergence rates of antibiotic resistant bacteria in a single clinic population comparing antiseptic technique with iodine vs. use of post-injection second generation fluoroquinolones has not been reported in the literature. 2. Objectives: The purpose of the study is to help determine the best way to prevent infection and limit antibiotic resistance in patients receiving eye injections. 3. Procedures Involved (Research Interventions): After the patient is chosen based on inclusion criteria and agrees to participate in the study, exclusion criteria will be reviewed, cognizance will be determined, informed consent and HIPAA compliance forms will be signed. At this point and prior to the instillation of ophthalmic medications, a Rayon swab will be passed along the inferior fornix of the study eye while the patient looks up and the examiner lowers the lower eyelid. The swab will then be used to inoculate chocolate agar and a blood agar culture plates and a glass slide. These will be brought to the FMO microbiology department for culture and Gram stain. All Staphylococcus aureus and coagulase negative Staphylococcus species identified will be subjected to sensitivity testing using the Gram Positive antibiotic panel available at Loma Linda, with the addition of ciprofloxacin.
NCT03862170 ↗	Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer	Suspended	CR-CSSS Champlain-Charles-Le Moyne	Phase 3	2015-02-10	Phase III study that aims to evaluate the necessity of prophylactic antibiotics use after HDR brachytherapy in the treatment of prostate adenocarcinomas.
NCT04212078 ↗	Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime	Recruiting	Santen Pharmaceutical Co., Ltd.	Phase 1/Phase 2	2019-07-29	Endophthalmitis is a clinical diagnosis made when intraocular inflammation involving both posterior and anterior chamber; is attributable to bacterial or fungal infection. It is a serious intraocular inflammatory disorder which can be spread via endogenous or exogenous access into the eye by infecting organism. Exogenous spread usually happens post intraocular surgery or procedure (i.e. cataract, vitrectomy, glaucoma filtration surgery) while endogenous spread is associated with hematogenous spread. The occurrence of endophthalmitis accounts for serious post-operative complication which can lead to severe vision loss and even blindness. There are several studies conducted to ascertain the efficiency of intracameral antibiotic as post-operative endophthalmitis prophylaxis. However, there is limited study in human using intracameral levofloxacin to evaluate its effect.This study is designed to compare between intracameral levofloxacin and intracameral cefuroxime in terms of corneal endothelial cell count and its morphology and central corneal thickness in uncomplicated phacoemulsification surgery

Clinical Trial Conditions for CILOXAN

Condition Name

Condition Name for CILOXAN
Intervention	Trials
Ear Diseases	2
Otitis	2
Otitis Externa	2
Otorhinolaryngologic Diseases	2

Condition MeSH

Condition MeSH for CILOXAN
Intervention	Trials
Otorhinolaryngologic Diseases	2
Otitis Externa	2
Otitis	2
Ear Diseases	2

Clinical Trial Locations for CILOXAN

Trials by Country

Trials by Country for CILOXAN
Location	Trials
Israel	2
Malaysia	1
Lebanon	1
Canada	1
United States	1

Trials by US State

Trials by US State for CILOXAN
Location	Trials
California	1

Clinical Trial Progress for CILOXAN

Clinical Trial Phase

Clinical Trial Phase for CILOXAN
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for CILOXAN
Clinical Trial Phase	Trials
Completed	3
Unknown status	1
Recruiting	1

Clinical Trial Sponsors for CILOXAN

Sponsor Name

Sponsor Name for CILOXAN
Sponsor	Trials
Otic Pharma	2
American University of Beirut Medical Center	1
Rafic Hariri University Hospital	1

Sponsor Type

Sponsor Type for CILOXAN
Sponsor	Trials
Other	5
Industry	3

CILOXAN (ciprofloxacin ophthalmic) Clinical Trials Update, Market Analysis and Projection

Last updated: April 27, 2026

What is CILOXAN and what products define the market?

CILOXAN is the brand name for ciprofloxacin hydrochloride in ophthalmic formulations. In the US, the brand is positioned around ocular antibacterial therapy and is typically sold as:

• CILOXAN Ophthalmic Solution (ciprofloxacin HCl)
• CILOXAN Ophthalmic Ointment (ciprofloxacin HCl)

CILOXAN’s market scope is therefore tied to topical ophthalmic antibiotic use cases, principally bacterial conjunctivitis and other localized bacterial ocular infections per labeling, with purchase patterns driven by clinician prescribing and pharmacy availability. The brand’s commercial trajectory is anchored to the continued availability of ciprofloxacin ophthalmic products in the same therapeutic segment.

What does the clinical-trials pipeline look like for CILOXAN?

Across registries, CILOXAN-branded programs are generally not the center of new late-stage development. The ciprofloxacin ophthalmic class has matured; most new clinical evidence in recent years tends to appear as comparative studies, formulation-specific work, or post-approval safety/real-world investigations rather than new, brand-sponsored phase programs.

Key structural implication for investors: for a mature ophthalmic antibiotic with longstanding regulatory history, “clinical trials update” typically means (1) ongoing or recently completed comparative studies involving ciprofloxacin ophthalmics, and (2) trials that evaluate endpoints such as time to symptom resolution, microbial eradication, and safety signals rather than novel mechanisms.

What late-stage and regulatory signals exist for ciprofloxacin ophthalmic products?

CILOXAN’s regulatory lifecycle is largely governed by the long-standing approval of ciprofloxacin ophthalmic products and the competitive pressure from generics and authorized alternatives. In this environment, major signals that move the commercial curve usually come from:

• Label expansions or refined indications (rare for mature antibiotics)
• Reformulations (new viscosity/vehicle changes, if pursued)
• Switching dynamics in pharmacies and formularies due to pricing and reimbursement

In the absence of brand-level late-stage “transformational” programs, the practical market driver is still class demand plus market share against substitutes rather than pipeline risk.

---

Clinical Trials Update (Evidence Landscape)

Where do ciprofloxacin ophthalmic studies cluster?

Clinical evidence for ciprofloxacin ophthalmic therapy clusters around:

• Acute bacterial conjunctivitis endpoints: time to improvement, proportion improved by day 2 to day 3, microbiological outcomes, and safety
• Safety/tolerability: ocular adverse events, corneal staining outcomes (when included), and discontinuation rates
• Comparative efficacy against other antibiotic classes (fluoroquinolones and broader antibiotic comparators)

Which trial categories most affect near-term perception of ciprofloxacin ophthalmics?

For a mature product, decision-makers usually track:

1. Comparative studies (ciprofloxacin vs other agents) that support “no worse” efficacy and acceptable safety
2. Real-world observational studies that inform prescriber confidence and guideline alignment
3. Pediatric and adult subgroup results tied to common prescribing populations

What is the practical “update” for CILOXAN?

The practical clinical update is that ciprofloxacin ophthalmic products continue to be supported by an established evidence base and ongoing comparative literature rather than brand-specific late-stage pivots. This keeps CILOXAN commercial risk lower on clinical uncertainty, while commercial upside is capped by competition and patent/market exclusivity dynamics.

---

Market Analysis

What market does CILOXAN compete in?

CILOXAN competes in the US topical ophthalmic antibiotic market, overlapping with:

• Generic ciprofloxacin ophthalmic solutions/ointments
• Other topical antibiotic classes (fluoroquinolones and non-fluoroquinolones depending on formulary preferences)
• Treatment shifts based on resistance patterns, guideline positioning, and payer restrictions

What are the dominant commercial constraints?

For CILOXAN-like mature ophthalmics, dominant constraints typically include:

• Generic substitution that compresses net pricing
• Class saturation where prescribers keep default products within a formulary
• Lower willingness to pay in uncomplicated bacterial conjunctivitis compared with higher-value ophthalmology segments (e.g., retina or specialty anti-inflammatory drugs)

Where does value still accrue?

Value can still accrue when:

• CILOXAN retains formulary placement where generics are less preferred (brand-specific contract dynamics)
• Stock availability and pharmacy dispensing patterns preserve access
• Clinical trust and familiarity reduce switching in certain prescriber segments

---

Market Projection (Near-Term Through Medium-Term)

How should the market be projected for CILOXAN?

Given the mature status of ciprofloxacin ophthalmic therapy, projections should be modeled as:

• Stable-to-slightly declining volume share (pricing pressure and generic share shift)
• Net sales sensitivity to pricing (contract pricing, rebates, and competitive entry)
• Low probability of pipeline-led acceleration unless a label expansion or formulation disruption emerges

Base-case projection structure

A defensible projection framework uses three levers:

1. Therapy demand: bacterial conjunctivitis incidence and prescribing behavior
2. Share against generics: brand retention vs dispensing economics
3. Net price trend: rebate compression and payer-driven substitution

Projection logic

• If generic penetration remains high and pharmacy contracts favor low-cost alternatives, brand net sales trend down even if overall therapy demand is steady.
• If CILOXAN maintains formulary access longer than competitors, decline can slow to a near-flat pattern.
• If payer restrictions tighten or new generic entrants increase substitution, decline accelerates.

Scenario outcomes (directional)

• Bull case: modest share resilience and stable prescribing patterns keep decline shallow; net sales drop is limited by contract stability.
• Base case: steady therapy demand, continued generic substitution drives continued net sales erosion.
• Bear case: deeper formulary restrictions and stronger competitive pricing accelerate net sales decline.

---

Strategic Implications for R&D and Investment

What does the mature clinical and competitive profile imply?

CILOXAN’s value proposition is no longer novelty-driven. It is operational and market-driven:

• Prescriber familiarity and guideline adherence support continued use.
• Competitive economics and generic substitution determine brand survival and profitability.

What moves the needle in this segment?

The needle moves with:

• Formulary and reimbursement shifts
• Pricing and rebate execution
• Any evidence-based expansions in use cases (rare)

---

Key Takeaways

• CILOXAN is a mature ciprofloxacin ophthalmic brand competing in the topical ophthalmic antibiotic market where generic substitution constrains growth.
• Clinical development updates for ciprofloxacin ophthalmics mainly track comparative and real-world evidence, not brand-defining late-stage innovation.
• Market outlook is driven by therapy demand stability plus share and pricing dynamics against generics, producing a directional projection of net sales erosion under normal competitive conditions.
• Investment and R&D decisions should treat CILOXAN-like products as commercial execution plays rather than pipeline-led growth bets.

---

FAQs

1. Is CILOXAN still the primary ciprofloxacin ophthalmic brand in the US?
   Brand use persists, but market economics are strongly influenced by generics and formulary contracts.

2. What endpoints do recent ciprofloxacin ophthalmic studies typically emphasize?
   Time to symptom improvement, clinical cure/improvement rates, microbiological outcomes when measured, and safety/tolerability.

3. Why do brand sales often decline even if total therapy demand is stable?
   Because generic substitution and rebate pressure reduce net pricing and brand share.

4. Does the ciprofloxacin ophthalmic category have ongoing clinical research?
   Yes, primarily comparative and post-approval evidence rather than brand-defining late-stage novelty.

5. What is the most likely near-term market driver for CILOXAN?
   Formulary placement and net pricing execution versus generics.

---

References (APA)

[1] CILOXAN (ciprofloxacin hydrochloride ophthalmic) product information and prescribing details, US labeling. (Access via FDA/US prescribing information sources).
[2] ClinicalTrials.gov. Search results for ciprofloxacin ophthalmic studies and related antibacterial conjunctivitis trial records. (Accessed via ClinicalTrials.gov database).